Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (3038)	5/16/2013 10:41:48 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3661

Merck can get this vaccine approved with a blindfold, if there are long-term survivors. Regulatory agencies aren't going to approve on this data, but they'll be asking for more of the same. That's a logical, predefined slice that doesn't create a subgroup. Slides at the presentation will be highly "scrutinized". 25% and falling. edit: I want to be clear about this. If you go to FDA with interesting results, they logically get interested. They're good scientists who want to help patients. The route with this vaccine is clear. Cytotoxic T cells, as I've mentioned many times over the years, can eat their way into Fort Knox. These results are real, the questions are whether they're mediated by "adjuvant effects" (foremost including, chuckle, adjuvant) or by antigen sensitization, and, if occasional long-term survivors stand out, can the frequency be goosed by ipi or such? After Feuerstein and a few newsletter guys are done and the raid is finished? The presentation will, imo, get plenty of buzz. I added at 2.16 and 2.06.